Gene therapy for lipoprotein lipase deficiency

Current Opinion in Lipidology

Volumn 23, Issue 4, 2012, Pages 310-320

  Gaudet, Daniel ^a   Méthot, Julie ^a   Kastelein, John ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

gene therapy; hyperchylomicronaemia; hypertriglyceridaemia; lipoprotein lipase; LPL deficiency

Indexed keywords

ALIPOGENE TIPARVOVEC; APOLIPOPROTEIN E; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; OLIGONUCLEOTIDE; TRIACYLGLYCEROL;

ACUTE ABDOMEN; AUTOSOMAL RECESSIVE DISORDER; CHIMEROPLASTY; GENE REPLACEMENT THERAPY; GENE THERAPY; HEPATOSPLENOMEGALY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; MUSCLE BIOPSY; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PANCREATITIS; PATHOGENESIS; PATIENT SAFETY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RARE DISEASE; REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA;

ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIPOPROTEIN LIPASE; SAFETY;

EID: 84863984123     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283555a7e     Document Type: Review

References (44)

1. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341-355.
2. Erratum in: Nat Rev Genet 2011; 12(7):515.
3. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011; 12:301-315.
4. Kamimura K, Suda T, Zhang G, Liu D. Advances in gene delivery systems. Pharmaceut Med 2011; 25:293-306.
5. Blaese RM, Culver KW, Miller AD, et al. Tlymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270:475-480.
6. Tagalakis AD, Graham IR, Riddell DR, et al. Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty. J Biol Chem 2001; 276:13226-13230.
7. Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012; 11:125-140.
8. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther 2012; 20:513-524.
9. Crooke RM, Graham MJ. Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. Clin Lipidol 2011; 6:675-692.
10. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:998-1006.
11. Kassim SH, Wilson JM, Rader DJ. Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. Clin Lipidol 2010; 5:793-809.
12. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6:335-341.
13. Kassim SH, Li H, Vandenberghe LH, et al. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One 2010; 5:e13424.
14. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res 1996; 37:693-707.
15. Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 2011; 22:247-253.
16. Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, Apo C-deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. 8th ed. New York, NY: McGraw-Hill; 2001. pp. 2789-2816.
17. Chait A, Brunzell JD. Chylomicronemia syndrome. Adv Intern Med 1992; 37:249-273.
18. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998; 27:551-567.
19. Tremblay K, Mé thot J, Brisson D, Gaudet D. Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol 2011; 5:37-44.
20. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol 2009; 20:497-504.
21. Brisson D, Mé thot J, Tremblay K, et al. Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics. Pharmacogenet Genomics 2010; 20:742-747.
22. Gaudet D, de Wal J, Tremblay K, et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 2010; 11:55-60.
23. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012 [Epub ahead of print].
24. Dallinga-Thie GM, Franssen R, Mooij HL, et al. The metabolism of triglyceriderich lipoproteins revisited: new players, new insight. Atherosclerosis 2010; 211:1-8.
25. Nilsson SK, Heeren J, Olivecrona G, Merkel M. Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis 2011; 219:15-21.
26. Young SG, Davies BS, Voss CV, et al. GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J Lipid Res 2011; 52:1869-1884.
27. Johansen CT, Wang J, Lanktree MB, et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 2010; 42:684-687.
28. Goldberg IJ, Merkel M. Lipoprotein lipase: physiology, biochemistry, and molecular biology. Front Biosci 2001; 6:D388-D405.
29. Razzaghi H, Day BW, McClure RJ, Kamboh MI. Structure-function analysis of D9N and N291S mutations in human lipoprotein lipase using molecular modelling. J Mol Graph Model 2001; 19:487-494.
30. Rip J, Nierman MC, Sierts JA, et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. Hum Gene Ther 2005; 16: 1276-1286.
31. Rip J, Nierman MC, Ross CJ, et al. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 2006; 26:1236-1245.
32. Ross CJ, Twisk J, Meulenberg JM, et al. Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation. Hum Gene Ther 2004; 15:906-919.
33. Ross CJ, Twisk J, Bakker AC, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 2006; 17:487-499.
34. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipasedeficient patients. Arterioscler Thromb Vasc Biol 2008; 28:2303-2304.
35. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009; 114:2077-2086.
36. Gaudet D, Mé thot J, Dé ry S, et al. Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial. Gene Ther 2012 (in press).
37. Carpentier A, Frisch F, Labbe SM, et al. Gene therapy with alipogene tiparvovec results in enhanced postprandial clearance of chylomicrons in LPLD patients. J Clin Endocrinol Metab 2012; 97:1635-1644.
38. Sadek S, Medina J, Arias M, et al. Neo Int-05 Study group. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: a prospective, multicenter, randomized study. Transplantation 2006; 74:511-517.
39. Ragni MV, Moore CG, Bias V, et al. Challenges of rare disease research: limited patients and competing priorities. Haemophilia 2012; 18:e192-e194.
40. Ortolano S, Spuch C, Navarro C. Present and future of adeno associated virus based gene therapy approaches. Recent Pat Endocr Metab Immune Drug Discov 2012; 6:47-66.
41. Dietz HC. New therapeutic approaches to Mendelian disorders. N Engl J Med 2010; 363:852-863.
42. Kimmelman J. The ethics of human gene transfer. Nat Rev Genet 2008; 9:239-244.
43. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1:91-99.
44. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011; 12:316-328.